Cannabinoid Research Firm Cannabis Science, Inc. Could Go Under
By Anne Holland [Updated as of 4/25/12] According to its annual 2012 report filed today, Cannabis Science, Inc. (PINK:CBIS), may be in danger of shutting its doors. The company’s Form 10-K stated, “At this time, our ability to generate any significant revenues continues to be uncertain. There is substantial doubt about our ability to continue as a going concern.” Although this type of doom-saying is normal for financial filings, which must include worst-case scenarios, Cannabis Science’s financials, as presented, do not appear to be encouraging. The company’s stock has been hovering just over 5 cents all day, compared to nearly 11 cents a year ago.
Despite this uncertainty, the company, which develops cannabinoid-based (CBD) therapies for the treatment of cancer and infectious diseases, is continuing to fight on. Just last month, it announced the appointment of another member of its scientific advisory board, Michael McGrath, a professor of medicine and lab medicine at the University of California, San Francisco. As we’ve reported in the past, credible medical studies have shown that CBDs may be effective in fighting some forms of cancer. The overall future of CBD-based treatments may be very bright indeed … but the legal situation surrounding them is still murky.
Although Cannabis Science only has two full-time employees, its general and administrative expenses increased by more than $1.2 million during 2012, from $3 million to $4.3 million, largely due to management and consulting fees owed under purchase agreements related to its acquisitions of GGECO University Inc and Cannabis Consulting, Inc. in the first quarter of 2012.
Several investor advisory publications and bloggers are using Cannabis Science as an example, saying MMJ-related stocks are altogether too risky for investors.
However, we feel this is too simplistic.
While the stock market itself is inherently risky, and due to legal factors MMJ-related stocks are even more so, some medical cannabis companies may be worth looking into. The key is to find companies with growing revenues in ancillary industries that do not depend entirely on FDA or other federal approval to continue.
Marijuana cultivation facilities have been specifically identified as a key contributor to Denver’s increasing electric [click to continue...]
Five Alaskans were appointed to a board that will craft laws governing the state’s recreational [click to continue...]
The New York Health Department may announce winners of the five medical cannabis licenses up [click to continue...]
The Green Rush is back on in Massachusetts. The opening of the first medical cannabis [click to continue...]
Rules governing Oregon’s recreational marijuana market are taking shape, with state lawmakers sending two bills [click to continue...]
Republican presidential candidate Rand Paul made a splash in Denver on Tuesday, raising an estimated [click to continue...]
Dispensaries could be open in Hawaii in just over a year, as a bill establishing [click to continue...]
In an attempt to get around obstructionists in the state House of Representatives who have [click to continue...]
And then there were five. Dispensaries permitted in New Jersey, that is. Compassionate Sciences, Inc. [click to continue...]
Louisiana Gov. Bobby Jindal has signed a bill making his state the latest in the [click to continue...]
In another sign of the marijuana industry’s growing national reach, a New York-based real estate [click to continue...]
Washington State growers and processors would no longer pay a 25% tax on cannabis and [click to continue...]
Delaware’s only licensed medical cannabis dispensary officially opened in the northern town of Wilmington on [click to continue...]
Canadian medical marijuana producer and distributor Tilray said it will lay off 61 employees as [click to continue...]